MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026)

MoonLake Immunotherapeutics' Share-based Compensation history runs 6 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 483.19% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $24.0 million (up 203.52% YoY), while the FY2025 annual figure was $12.9 million, up 77.12% from the prior year.
• Share-based Compensation was $13.4 million for Q1 2026 at MoonLake Immunotherapeutics, up from $3.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $13.4 million in Q1 2026 to a low of $1.4 million in Q3 2023.
• Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.3 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation tumbled 71.32% in 2022, then surged 483.19% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $2.6 million in 2022, then tumbled by 38.17% to $1.6 million in 2023, then climbed by 20.46% to $1.9 million in 2024, then jumped by 85.63% to $3.6 million in 2025, then jumped by 272.01% to $13.4 million in 2026.
• The last three Share-based Compensation figures came in at $13.4 million (Q1 2026), $3.6 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.